Direct-to-consumer advertising of prescription drugs: Does it add to the overuse and inappropriate use of prescription drugs or alleviate underuse?

International Journal of Pharmaceutical Medicine

Volumn 20, Issue 1, 2006, Pages 17-24

  Donohue, Julie M ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSUMER ADVOCACY; COST BENEFIT ANALYSIS; DOCTOR PATIENT RELATION; DRUG CONTROL; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG USE; HEALTH CARE POLICY; HUMAN; MEDICAL INFORMATION; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; UNITED STATES;

EID: 33745483805     PISSN: 13649027     EISSN: 13649027     Source Type: Journal    
DOI: 10.2165/00124363-200620010-00002     Document Type: Article

References (52)

1. Food and Drug Administration, Department of Health and Human Services. Guidance for industry: broadcast advertising of prescription drugs, August 1999 [online]. Available from URL: http://www.fda.gov/cder/guidance/ 1804fnl.htm [Accessed 2005 Feb 15]
2. Hoek J, Gendall P, Calfee J. Direct-to-consumer advertising of prescription medicines in the United States and New Zealand: an analysis of regulatory approaches and consumer responses. Int J Advertising 2004; 23: 197-227
3. IMS Health. Top line industry data: promotion [online]. Available from URL: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_49695992_ 75406357,00.html [Accessed 2005 Feb 15]
4. 50th Annual 100 leading national advertisers. Advertising Age 2005 Jun 27 [online]. Available from URL: http://www.adage.com/paypoints/buyArticle.cms/ login?.articleId=49238&auth= [Accessed 2005 Feb 15]
5. Calfee JE. What do we know about direct-to-consumer advertising of prescription drugs? Health Aff 2003 Feb 26; 116-9 [online]. Available from URL: http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.116v1/DC1 [Accessed 2005 Feb 15]
6. Kelly P. DTC advertising's benefits far outweigh its imperfections. Health Aff 2004 Apr 28; 246-8 [online]. Available from URL: http://content. healthaffairs.org/cgi/content/full/hlthaff.w4.246v1/DC1 [Accessed 2005 Feb 15]
7. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 1999 Jan 27; 281 (4): 380-1
8. Homer AF. Direct-to-consumer advertising: strengthening our health care system. N Engl J Med 2002; 346 (7): 526-8
9. Weissman JS, Blumenthal D, Silk AJ, et al. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff 2003 Feb; W3-82-95 [online]. Available from URL: http://content.healthaffairs.org/cgi/ content/abstract/hlthaff.w3.82v1 [Accessed 2003 Jun 28]
10. Food and Drug Administration, Office of Medical Policy, Division of Drug Marketing, Advertising and Communications. Attitudes and behaviors associated with direct-to-consumer (DTC) promotion of prescription drugs: main survey results [online]. Available from URL: http://www.fda.gov/cder/ddmac/dtcindex.htm [Accessed 2005 Feb 15]
11. Consumer reaction to DTCA of prescription medicines. Prevention Magazine 2002/2003; 45-54
12. Angell M. The truth about drug companies. New York: Random House, 2004
13. Mintzes B. Direct to consumer advertising is medicalising normal human experience. BMJ 2002; 324: 908-11
14. Relman AS. Direct-to-consumer advertising: what are the consequences? Testimony before the US Senate Special Committee on Aging; 2003 Jul 22 [online]. Available from URL: http://aging.senate.gov/public/index.cfm?Fuseaction= Hearings.Detail&HearingID=26 [Accessed 2003 Sep 2]
15. Hollon MF. Direct-to-consumer marketing of prescription drugs. CNS Drugs 2004; 18 (2): 69-77
16. Wolfe SM. Direct-to-consumer advertising: education or emotion promotion. N Engl J Med 2002 Feb 14; 346 (7): 524-6
17. Avorn J. Advertising and prescription drugs: promotion, education, and the public's health. Health Aff 2003 Feb 26; 104-8 [online]. Available from URL: http://content.healthaffairs.org/cgi/content/full/hlthaff.w3.104v1/DC1 [Accessed 2006 Feb 15]
18. Bell R, Kravitz R, Wilkes M. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract 2000; 49 (12): 1092-8
19. Woloshin S, Schwartz LM, Tremmel J, et al. Direct-to-consumer advertising for prescription drugs: what are Americans being sold? Lancet 2001; 358 (9288): 1141-6
20. Woloshin S, Schwartz LM, Welch HC. The value of benefit data in direct-to-consumer drug ads. Health Aff Web Exclusive 2004 Apr 28; W4: 234-45
21. Kaphingst KA, Rudd RE, DeJong W, et al. Literacy demands of product information intended to supplement television direct-to-consumer prescription drug advertisements. Patient Educ Couns 2004; 55: 293-300
22. Kaphingst KA, DeJong W. The educational potential of direct-to-consumer prescription drug advertising. Health Aff 2004; 23 (4): 143-50
23. Kaphingst KA, DeJong W, Rudd RE, et al. A content analysis of direct-to-consumer television prescription drug advertisements. J Health Commun 2004; 9: 515-28
24. Huh J. Is the information 'fair and balanced' in direct-to-consumer prescription drug websites? J Health Commun 2004; 9: 529-40
25. Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200-9
26. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug misuse. Clin Geriatr Med 1992; 8: 143-58
27. Gurwitz JH. Suboptimal medication use in the elderly: the tip of the iceberg. JAMA 1994; 272: 316-7
28. Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994; 42: 1241-7
29. Beers MH, Ouslander JG, Rolllingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151: 1825-32
30. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. CMAJ 1994; 150: 1801-9
31. Lipton HL, Bero LA, Bird JA, et al. Under medication among geriatric outpatients: results of a randomized controlled trial. Annu Rev Gerontol Geriatr 1992; 12: 95-108
32. Donohue JM, Berndt ER, Epstein AM, et al. Effects of pharmaceutical promotion adherence to guideline treatment of depression. Med Care 2004; 42 (12): 1176-85
33. Wosinska M. Direct-to-consumer advertising and drug therapy compliance. J Mark Res 2005; XLII: 323-32
34. Spence MM, Cheetham TC, Schweitzer SO, et al. Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005; 62 (5): 544-59
35. Kravitz RL, Epstein RM, Fedlman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants. JAMA 2005; 293 (16): 1995-2002
36. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346 (7): 498-505
37. Ma J, Stafford RS, Cockburn IM, et al. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther 2003; 25 (5): 1503-17
38. Berndt ER. The United States' experience with direct-to-consumer advertising of prescription drugs: what have we learned? International Conference on Pharmaceutical Innovation; 2005 May 25-27; Taipei [online]. Available from URL: http://www.icpi2005.org/download/Session%20B4- Ernst%20Berndt.PDF [Accessed 2006 Feb 15]
39. Neslin SA. ROI Analysis of Pharmaceutical Promotion (RAPP) study. Hanover (NH): Amos Tuck School of Business, Dartmouth [online]. Available from URL: http://www.rxpromoroi.org/rapp [Accessed 2006 Feb 15]
40. Iizuka T. What explains the use of direct-to-consumer advertising of prescription drugs? J Ind Econ 2004; 52 (3): 349-79
41. Rosenthal MB, Berndt ER, Donohue JM, et al. Demand effects of recent changes in prescription drug promotion. The Henry J. Kaiser Family Foundation. 2003 Jun [online]. Available from URL: http://www.kff.org/rxdrugs/loader.cfm? url=/commonspot/security/getfile.cfm&PageID=14380 [Accessed 2005 Feb 16]
42. Narayanan S, Desiraju R, Chintagunta PK. Return on investment implications for pharmaceutical promotional expenditures: the role of marketing-mix interactions. J Marketing 2004 Oct; 68: 90-105
43. Wosinska M. Just what the patient ordered? Direct-to-consumer advertising and the demand for pharmaceutical products. HBS Marketing Research Paper No. 02-04 [online]. Available from URL: http://ssrn.com/abstract=347005 [Accessed 2006 Feb 15]
44. Hansen RA, Schommer JC, Cline RR, et al. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use. Res Social Adminstrative Pharm 2005; 1: 139-57
45. Donohue JM, Berndt ER. Direct-to-consumer advertising and choice of antidepressant. J Public Policy Marketing 2004; 23 (2): 115-27
46. Ling DC, Berndt ER, Kyle MK. Deregulating direct-to-consumer marketing of prescription drugs: effects on prescription and over-the-counter product sales. J Law Econ 2002; XLV: 691-723
47. Calfee JE, Winston C, Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J Law Econ 2002; 45: 673-90
48. Iizuka T, Jin GZ. The effect of prescription drug advertising on drug visits. J Econ Manag Strat 2005; 14 (3): 701-27
49. Brekke KR, Kuhn M. Direct-to-consumer advertising in pharmaceutical markets. J Health Econ 2006; 25: 102-30
50. Henney JE. Challenges in regulating direct-to-consumer advertising. JAMA 2000; 284 (17): 2242
51. Saul S. Senate leader calls for limits on drug ads. NY Times 2005 Jul 2: Section C 13
52. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the US. N Engl J Med 2003; 348 (26): 2635-45